Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?
The standard of care for patients with local advanced or metastatic urothelial carcinoma is chemotherapy. However, results with this are rather disappointing, and validated prognostic factors and biomarkers of tumor response, which are useful in the decision-making process, are still lacking. PubMed...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2015-01, Vol.11 (1), p.107-119 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119 |
|---|---|
| container_issue | 1 |
| container_start_page | 107 |
| container_title | Future oncology (London, England) |
| container_volume | 11 |
| creator | Buti, Sebastiano Ciccarese, Chiara Zanoni, Daniele Santoni, Matteo Modena, Alessandra Maines, Francesca Gilli, Annalisa Bria, Emilio Brunelli, Matteo Rimanti, Anita Cascinu, Stefano Ardizzoni, Andrea Tortora, Giampaolo Massari, Francesco |
| description | The standard of care for patients with local advanced or metastatic urothelial carcinoma is chemotherapy. However, results with this are rather disappointing, and validated prognostic factors and biomarkers of tumor response, which are useful in the decision-making process, are still lacking. PubMed databases were searched for articles published until November 2013. Several promising clinical and biological candidate prognostic factors or markers of tumor response to first- or second-line therapy, such as hemoglobin, performance status, visceral metastasis and ERCC1, hENT1 and EMT markers, have been identified and described in this article. In summary, clinical parameters and molecular profiling could revolutionize the management of local advanced or metastatic urothelial cancer, but an improvement in individualized therapeutic approaches still seems distant. |
| doi_str_mv | 10.2217/fon.14.172 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1645775582</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A412067349</galeid><sourcerecordid>A412067349</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-77ce62d8f94c12cbbdcb1f4a105b6c6bcbf0cc16bcf1b519dc7987588bf3e6c33</originalsourceid><addsrcrecordid>eNptkV-L1TAQxYso7rr64geQgC8i9NqkadL6IsviP1jQB30O6WSyN0ub1CTdy_rpTbmrqCx5yMzJb04GTlU9p82OMSrf2OB3lO-oZA-qUyo5r_u2oQ9LzeVQCzHwk-pJStdNw2XbNY-rE9Z1kslenFY_v8Zw5UPKDoj2hiwRjYPsbpBYDTnERJwni84OfU4kR9QZDTm4vCewxznkPUa93BIbItHmRnsoz2vc9MnpicCmxLfkUDgkJpADkpTLV--eVo-snhI-u7vPqu8f3n-7-FRffvn4-eL8sgbOhlxLCSiY6e3AgTIYRwMjtVzTphsFiBFG2wDQUlg6dnQwIIdedn0_2hYFtO1Z9erou8TwY8WU1ewS4DRpj2FNigreSdl1PSvoy__Q67BGX7bbKNlK2v9NXekJlfM25KhhM1XnnLJGyJYPhdrdQ5VjcHYQPFpX9H8GXh8HIIaUIlq1RDfreKtoo7agVQlaUa5K0AV-cbfpOs5o_qC_ky2AOAJ2zWvEBCVAQHXs5i1k5_E-519fqreB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1647371882</pqid></control><display><type>article</type><title>Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?</title><source>MEDLINE</source><source>PubMed Central</source><creator>Buti, Sebastiano ; Ciccarese, Chiara ; Zanoni, Daniele ; Santoni, Matteo ; Modena, Alessandra ; Maines, Francesca ; Gilli, Annalisa ; Bria, Emilio ; Brunelli, Matteo ; Rimanti, Anita ; Cascinu, Stefano ; Ardizzoni, Andrea ; Tortora, Giampaolo ; Massari, Francesco</creator><creatorcontrib>Buti, Sebastiano ; Ciccarese, Chiara ; Zanoni, Daniele ; Santoni, Matteo ; Modena, Alessandra ; Maines, Francesca ; Gilli, Annalisa ; Bria, Emilio ; Brunelli, Matteo ; Rimanti, Anita ; Cascinu, Stefano ; Ardizzoni, Andrea ; Tortora, Giampaolo ; Massari, Francesco</creatorcontrib><description>The standard of care for patients with local advanced or metastatic urothelial carcinoma is chemotherapy. However, results with this are rather disappointing, and validated prognostic factors and biomarkers of tumor response, which are useful in the decision-making process, are still lacking. PubMed databases were searched for articles published until November 2013. Several promising clinical and biological candidate prognostic factors or markers of tumor response to first- or second-line therapy, such as hemoglobin, performance status, visceral metastasis and ERCC1, hENT1 and EMT markers, have been identified and described in this article. In summary, clinical parameters and molecular profiling could revolutionize the management of local advanced or metastatic urothelial cancer, but an improvement in individualized therapeutic approaches still seems distant.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon.14.172</identifier><identifier>PMID: 25572786</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>bladder cancer ; Cancer research ; Carcinoma, Transitional Cell - drug therapy ; Carcinoma, Transitional Cell - pathology ; Chemotherapy ; Cisplatin - therapeutic use ; elderly patients ; Humans ; Neoplasm Metastasis ; Neoplasm Staging ; Patient outcomes ; Precision medicine ; Prognosis ; prognostic factor ; survival ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - pathology ; Urologic cancer ; urothelial cancer ; Urothelium - drug effects ; Urothelium - pathology</subject><ispartof>Future oncology (London, England), 2015-01, Vol.11 (1), p.107-119</ispartof><rights>COPYRIGHT 2015 Future Medicine Ltd.</rights><rights>2015 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-77ce62d8f94c12cbbdcb1f4a105b6c6bcbf0cc16bcf1b519dc7987588bf3e6c33</citedby><cites>FETCH-LOGICAL-c429t-77ce62d8f94c12cbbdcb1f4a105b6c6bcbf0cc16bcf1b519dc7987588bf3e6c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25572786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buti, Sebastiano</creatorcontrib><creatorcontrib>Ciccarese, Chiara</creatorcontrib><creatorcontrib>Zanoni, Daniele</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Modena, Alessandra</creatorcontrib><creatorcontrib>Maines, Francesca</creatorcontrib><creatorcontrib>Gilli, Annalisa</creatorcontrib><creatorcontrib>Bria, Emilio</creatorcontrib><creatorcontrib>Brunelli, Matteo</creatorcontrib><creatorcontrib>Rimanti, Anita</creatorcontrib><creatorcontrib>Cascinu, Stefano</creatorcontrib><creatorcontrib>Ardizzoni, Andrea</creatorcontrib><creatorcontrib>Tortora, Giampaolo</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><title>Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>The standard of care for patients with local advanced or metastatic urothelial carcinoma is chemotherapy. However, results with this are rather disappointing, and validated prognostic factors and biomarkers of tumor response, which are useful in the decision-making process, are still lacking. PubMed databases were searched for articles published until November 2013. Several promising clinical and biological candidate prognostic factors or markers of tumor response to first- or second-line therapy, such as hemoglobin, performance status, visceral metastasis and ERCC1, hENT1 and EMT markers, have been identified and described in this article. In summary, clinical parameters and molecular profiling could revolutionize the management of local advanced or metastatic urothelial cancer, but an improvement in individualized therapeutic approaches still seems distant.</description><subject>bladder cancer</subject><subject>Cancer research</subject><subject>Carcinoma, Transitional Cell - drug therapy</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Chemotherapy</subject><subject>Cisplatin - therapeutic use</subject><subject>elderly patients</subject><subject>Humans</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Patient outcomes</subject><subject>Precision medicine</subject><subject>Prognosis</subject><subject>prognostic factor</subject><subject>survival</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urologic cancer</subject><subject>urothelial cancer</subject><subject>Urothelium - drug effects</subject><subject>Urothelium - pathology</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkV-L1TAQxYso7rr64geQgC8i9NqkadL6IsviP1jQB30O6WSyN0ub1CTdy_rpTbmrqCx5yMzJb04GTlU9p82OMSrf2OB3lO-oZA-qUyo5r_u2oQ9LzeVQCzHwk-pJStdNw2XbNY-rE9Z1kslenFY_v8Zw5UPKDoj2hiwRjYPsbpBYDTnERJwni84OfU4kR9QZDTm4vCewxznkPUa93BIbItHmRnsoz2vc9MnpicCmxLfkUDgkJpADkpTLV--eVo-snhI-u7vPqu8f3n-7-FRffvn4-eL8sgbOhlxLCSiY6e3AgTIYRwMjtVzTphsFiBFG2wDQUlg6dnQwIIdedn0_2hYFtO1Z9erou8TwY8WU1ewS4DRpj2FNigreSdl1PSvoy__Q67BGX7bbKNlK2v9NXekJlfM25KhhM1XnnLJGyJYPhdrdQ5VjcHYQPFpX9H8GXh8HIIaUIlq1RDfreKtoo7agVQlaUa5K0AV-cbfpOs5o_qC_ky2AOAJ2zWvEBCVAQHXs5i1k5_E-519fqreB</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Buti, Sebastiano</creator><creator>Ciccarese, Chiara</creator><creator>Zanoni, Daniele</creator><creator>Santoni, Matteo</creator><creator>Modena, Alessandra</creator><creator>Maines, Francesca</creator><creator>Gilli, Annalisa</creator><creator>Bria, Emilio</creator><creator>Brunelli, Matteo</creator><creator>Rimanti, Anita</creator><creator>Cascinu, Stefano</creator><creator>Ardizzoni, Andrea</creator><creator>Tortora, Giampaolo</creator><creator>Massari, Francesco</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150101</creationdate><title>Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?</title><author>Buti, Sebastiano ; Ciccarese, Chiara ; Zanoni, Daniele ; Santoni, Matteo ; Modena, Alessandra ; Maines, Francesca ; Gilli, Annalisa ; Bria, Emilio ; Brunelli, Matteo ; Rimanti, Anita ; Cascinu, Stefano ; Ardizzoni, Andrea ; Tortora, Giampaolo ; Massari, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-77ce62d8f94c12cbbdcb1f4a105b6c6bcbf0cc16bcf1b519dc7987588bf3e6c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>bladder cancer</topic><topic>Cancer research</topic><topic>Carcinoma, Transitional Cell - drug therapy</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Chemotherapy</topic><topic>Cisplatin - therapeutic use</topic><topic>elderly patients</topic><topic>Humans</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Patient outcomes</topic><topic>Precision medicine</topic><topic>Prognosis</topic><topic>prognostic factor</topic><topic>survival</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urologic cancer</topic><topic>urothelial cancer</topic><topic>Urothelium - drug effects</topic><topic>Urothelium - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buti, Sebastiano</creatorcontrib><creatorcontrib>Ciccarese, Chiara</creatorcontrib><creatorcontrib>Zanoni, Daniele</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Modena, Alessandra</creatorcontrib><creatorcontrib>Maines, Francesca</creatorcontrib><creatorcontrib>Gilli, Annalisa</creatorcontrib><creatorcontrib>Bria, Emilio</creatorcontrib><creatorcontrib>Brunelli, Matteo</creatorcontrib><creatorcontrib>Rimanti, Anita</creatorcontrib><creatorcontrib>Cascinu, Stefano</creatorcontrib><creatorcontrib>Ardizzoni, Andrea</creatorcontrib><creatorcontrib>Tortora, Giampaolo</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buti, Sebastiano</au><au>Ciccarese, Chiara</au><au>Zanoni, Daniele</au><au>Santoni, Matteo</au><au>Modena, Alessandra</au><au>Maines, Francesca</au><au>Gilli, Annalisa</au><au>Bria, Emilio</au><au>Brunelli, Matteo</au><au>Rimanti, Anita</au><au>Cascinu, Stefano</au><au>Ardizzoni, Andrea</au><au>Tortora, Giampaolo</au><au>Massari, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>11</volume><issue>1</issue><spage>107</spage><epage>119</epage><pages>107-119</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>The standard of care for patients with local advanced or metastatic urothelial carcinoma is chemotherapy. However, results with this are rather disappointing, and validated prognostic factors and biomarkers of tumor response, which are useful in the decision-making process, are still lacking. PubMed databases were searched for articles published until November 2013. Several promising clinical and biological candidate prognostic factors or markers of tumor response to first- or second-line therapy, such as hemoglobin, performance status, visceral metastasis and ERCC1, hENT1 and EMT markers, have been identified and described in this article. In summary, clinical parameters and molecular profiling could revolutionize the management of local advanced or metastatic urothelial cancer, but an improvement in individualized therapeutic approaches still seems distant.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>25572786</pmid><doi>10.2217/fon.14.172</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2015-01, Vol.11 (1), p.107-119 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1645775582 |
| source | MEDLINE; PubMed Central |
| subjects | bladder cancer Cancer research Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Chemotherapy Cisplatin - therapeutic use elderly patients Humans Neoplasm Metastasis Neoplasm Staging Patient outcomes Precision medicine Prognosis prognostic factor survival Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urologic cancer urothelial cancer Urothelium - drug effects Urothelium - pathology |
| title | Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T13%3A38%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20and%20predictive%20factors%20in%20patients%20treated%20with%20chemotherapy%20for%20advanced%20urothelial%20cancer:%20where%20do%20we%20stand?&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Buti,%20Sebastiano&rft.date=2015-01-01&rft.volume=11&rft.issue=1&rft.spage=107&rft.epage=119&rft.pages=107-119&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon.14.172&rft_dat=%3Cgale_proqu%3EA412067349%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1647371882&rft_id=info:pmid/25572786&rft_galeid=A412067349&rfr_iscdi=true |